Dataset Information

Immunopeptidome of Human Renal Cell Carcinoma (RCC) derived cells infected with oncolytic viruses.

ABSTRACT: In this study we demonstrate the effect of oncolytic adenoviruses armed with CXCL9, CXCL10 and IL-15 to infect cancer cells, secrete the encoded protein and drive gradient-dependent T-cell attraction. Our in vivo validation demonstrated an increased intratumoral CD4+ and CD8+ T-cell infiltration following treatment with armed viruses compared to control groups. Finally, RCC cells were screened for tumor-specific peptides to validate their immunogenicity in a (personalized) oncolytic cancer vaccine approach, previously referred to as PeptiCRAd.

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Cell Culture

DISEASE(S): Renal Cell Carcinoma

SUBMITTER: Rui Branca

LAB HEAD: Janne Lehtiö

PROVIDER: PXD051880 | Pride | 2025-05-06

REPOSITORIES: Pride

ACCESS DATA

Dataset's files

Source:

			Action	DRS
	Ligandomes_human-RCC_2023may_cosmic_mutanome_search.tgz	Other
	Ligandomes_human-RCC_2023may_cosmic_mutanome_search_peptides_and_sample_map.xlsx	Xlsx
	Ligandomes_human-RCC_2023may_neoepitope_search.tgz	Other
	Ligandomes_human-RCC_2023may_neoepitope_search_peptides_and_sample_map.xlsx	Xlsx
	Sara_Feola_human-RCC_s1_786-0-r1-30pc_30min_CEO-truck-MHC_Slot2-10_2023-05-17_1217.d.zip	Other

Items per page:

1 - 5 of 11

Publications

Enhancing T-cell recruitment in renal cell carcinoma with cytokine-armed adenoviruses.

Feodoroff Michaela M Hamdan Firas F Antignani Gabriella G Feola Sara S Fusciello Manlio M Russo Salvatore S Chiaro Jacopo J Välimäki Katja K Pellinen Teijo T Branca Rui M RM Lehtiö Janne J D Alessio Federica F Bottega Paolo P Stigzelius Virpi V Sandberg Janita J Clancy Jonna J Partanen Jukka J Malmstedt Minna M Rannikko Antti A Pietiäinen Vilja V Grönholm Mikaela M Cerullo Vincenzo V

Oncoimmunology 20240925 1

Immunotherapy has emerged as a promising approach for cancer treatment, with oncolytic adenoviruses showing power as immunotherapeutic agents. In this study, we investigated the immunotherapeutic potential of an adenovirus construct expressing CXCL9, CXCL10, or IL-15 in clear cell renal cell carcinoma (ccRCC) tumor models. Our results demonstrated robust cytokine secretion upon viral treatment, suggesting effective transgene expression. Subsequent analysis using resistance-based transwell migrat ...[more]

PMID: 39351443

Similar Datasets

Project description:Replicating viruses have broad applications in biomedicine, notably in cancer virotherapy and in the design of attenuated vaccines, however uncontrolled virus replication in vulnerable tissues can give pathology and often restricts the use of potent strains. Increased knowledge of tissue-selective microRNA expression now affords the possibility of engineering replicating viruses that are attenuated at the RNA level in sites of potential pathology, but retain wild type replication activity at sites not expressing the relevant microRNA. To assess the usefulness of this approach for the DNA virus, adenovirus, we have engineered a hepatocyte-safe wild type adenovirus 5 (Ad5), which normally mediates significant toxicity and is potentially lethal in mice. To do this we have included binding sites for hepatocyte-selective microRNA122a within the 3' UTR of the E1A transcription cassette. Imaging versions of these viruses, produced by fusing E1A with luciferase, showed that inclusion of microRNA122a binding sites caused up to 80 fold decreased hepatic expression of E1A following intravenous delivery to mice. Animals administered a ten-times lethal dose of wild type Ad5 (5 x 1010 viral particles/mouse) showed substantial hepatic genome replication and extensive liver pathology, while inclusion of 4 microRNA binding sites decreased replication 50-fold and virtually abrogated liver toxicity. This modified wild type virus retained full activity within cancer cells and provides a potent, liver-safe oncolytic virus. In addition to providing many potent new viruses for cancer virotherapy, microRNA-control of virus replication should provide a new strategy for designing safe attenuated vaccines applied across a broad range of viral diseases. four groups which we had were: WT: RNA extracted from livers of mice treated with wild type Ad5, 3 Replicates miR: RNA extracted from livers of mice treated with wild type Ad5 bearing mir122-binding sites in the 3'UTR of E1A (3 Replicates) Luc: RNA extracted from livers of mice treated with non-replicating Ad5 (3 Replicates) PBS: RNA extracted from livers of mice treated with PBS only (3 Replicates)